Related Experiment Video
Updated: Mar 5, 2026

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
Published on: January 27, 2019
Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status
Héctor Rodríguez-Angulo1, Juan Marques2, Ivan Mendoza2
1Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela. hrodrigu@ivic.gob.ve.
Insights
This study reveals that elevated Interleukin-2 (IL-2) levels in Chagas disease patients may indicate a high risk of sudden death and serve as a marker for treatment effectiveness. Amiodarone shows potential as an anti-inflammatory coadjuvant therapy.
Area of Science:
- Immunology
- Infectious Diseases
- Cardiology
Background:
- Chagas disease, caused by Trypanosoma cruzi, leads to heart failure and sudden death.
- Predicting disease progression and treatment response in Chagas disease is complex.
- Understanding the immune profile of patients is crucial for effective management.
Purpose of the Study:
- To analyze the Th1/Th17 and Th2 serum cytokine profiles in Venezuelan Chagas disease patients.
- To stratify patients based on amiodarone treatment, hypertension, and arrhythmias.
- To identify immune markers associated with disease risk and treatment efficacy.
Main Methods:
- Cytokine levels (IL-6, IL-2, TNF, IL-17, IFN-γ, IL-4, IL-10) were measured using Multiplexed Bead-Based Immunoassays in 38 patients.
- Statistical analysis included ANOVA to compare groups.
- Linear Discriminant Analysis (LDA) assessed cytokine discriminatory power.
Main Results:
- Significantly higher cytokine levels were observed in untreated patients at high risk of sudden death.
- IL-2, IFN-γ, and IL-10 were identified as key discriminators between high-risk/untreated and low-risk/treated groups.
- Elevated IL-2 levels correlated with high-risk of sudden death.
Conclusions:
- High IL-2 levels may identify patients at high risk of sudden death and serve as a treatment efficacy marker.
- Amiodarone demonstrated an anti-inflammatory and immunomodulatory effect in Chagas disease.
- Amiodarone could be a potential coadjuvant therapy for chronic Chagas disease.
Background:
Chagas disease is caused by the protozoan Trypanosoma cruzi and is characterized by heart failure and sudden death. Identifying which factors are involved in evolution and treatment response is actually challenging. Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10) serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and arrhythmias.
Methods:
Sera from 38 chagasic patients were analyzed to determine the level of cytokines by Multiplexed Bead-Based Immunoassays. ANOVA test was applied to determine differences for each group. Additionally, a Linear Discriminant Analysis (LDA) was applied to observe the accuracy of different cytokines to discriminate between the groups.
Results:
The levels of several cytokines were significantly higher in the high-risk of sudden death and untreated group. LDA showed that IL-2, IFN-γ and IL-10 were the best cytokines for discriminating between high-risk of sudden death and untreated patients versus low-risk of sudden death, treated and control groups.
Conclusions:
High IL-2 levels seem to identify patients with high-risk of sudden death and seems adequate as treatment efficacy marker. To our knowledge, this is the first report about the anti-inflammatory role of the amiodarone in Chagas disease, suggesting an inmunomodulatory effect that may be exploited as coadjutant therapy in chronic Chagas disease.
Related Concept Videos
Dysrhythmias II: Classification of Tachyarrhythmias
Myocarditis II: Clinical Features and Diagnostic Tests
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Acute Coronary Syndrome III: Diagnostic Studies

